EIM
HAE icon

Emerson Investment Management’s Haemonetics HAE Stock Holding History

Emerson Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-33,224
Closed -$1.32M – 142
2013
Q3 		$1.32M Sell
33,224
-5,196
-14% -$218K 0.3% 78
2013
Q2 		$1.59M Buy
+38,420
New +$1.56M 0.37% 72

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Emerson Investment Management's HAE Position: Q4 2013 in Review

Emerson Investment Management sold out of Haemonetics (HAE) in Q4 2013, closing a stake of 33,224 shares — an estimated $1.32M sold.

Emerson Investment Management first reported a position in HAE in Q2 2013 and held it in 2 quarters. The position peaked at $1.59M in Q2 2013. 195 funds tracked by Wall St. Rank hold HAE as of Q4 2013.

  • Emerson Investment Management reported no remaining Haemonetics position as of Q4 2013 after selling out during the quarter.
  • Emerson Investment Management sold 33,224 Haemonetics shares in Q4 2013, an estimated $1.32M.
  • Emerson Investment Management first reported a position in Haemonetics in Q2 2013 and held it in 2 quarters.
  • Emerson Investment Management's Haemonetics position peaked at $1.59M in Q2 2013.
  • 195 funds tracked by Wall St. Rank held Haemonetics as of Q4 2013.

Based on Emerson Investment Management's 13F filing for Q4 2013, filed 7 Feb 2014.